139 related articles for article (PubMed ID: 30468339)
1. Iron status in dogs with myxomatous mitral valve disease.
Savarese A; Probo M; Locatelli C; Gazzonis AL; Zanzani SA; Traini G; Vitiello T; Brambilla PG
Pol J Vet Sci; 2018 Sep; 21(3):507-515. PubMed ID: 30468339
[TBL] [Abstract][Full Text] [Related]
2. Iron parameters analysis in dogs with myxomatous mitral valve disease.
Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
[TBL] [Abstract][Full Text] [Related]
3. Preliminary Investigation of Cardiovascular-Renal Disorders in Dogs with Chronic Mitral Valve Disease.
Martinelli E; Locatelli C; Bassis S; Crosara S; Paltrinieri S; Scarpa P; Spalla I; Zanaboni AM; Quintavalla C; Brambilla P
J Vet Intern Med; 2016 Sep; 30(5):1612-1618. PubMed ID: 27717188
[TBL] [Abstract][Full Text] [Related]
4. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
Mangkhang K; Punyapornwithaya V; Tankaew P; Pongkan W; Chattipakorn N; Boonyapakorn C
Pol J Vet Sci; 2018 Dec; 21(4):673-680. PubMed ID: 30605282
[TBL] [Abstract][Full Text] [Related]
5. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
Müller S; Menciotti G; Borgarelli M
J Vet Cardiol; 2017 Oct; 19(5):433-440. PubMed ID: 28964709
[TBL] [Abstract][Full Text] [Related]
6. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease and dilated cardiomyopathy.
Ware WA; Lund DD; Subieta AR; Schmid PG
J Am Vet Med Assoc; 1990 Dec; 197(11):1475-81. PubMed ID: 2272879
[TBL] [Abstract][Full Text] [Related]
7. Left atrial deformation and phasic function determined by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease.
Caivano D; Rishniw M; Birettoni F; Patata V; Giorgi ME; Porciello F
J Vet Cardiol; 2018 Apr; 20(2):102-114. PubMed ID: 29459124
[TBL] [Abstract][Full Text] [Related]
8. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
[TBL] [Abstract][Full Text] [Related]
9. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
Wolf J; Gerlach N; Weber K; Klima A; Wess G
J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
[TBL] [Abstract][Full Text] [Related]
10. Circulating concentrations of insulin-like growth factor-1 in dogs with naturally occurring mitral regurgitation.
Pedersen HD; Falk T; Häggström J; Tarnow I; Olsen LH; Kvart C; Nielsen MO
J Vet Intern Med; 2005; 19(4):528-32. PubMed ID: 16095170
[TBL] [Abstract][Full Text] [Related]
11. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
[TBL] [Abstract][Full Text] [Related]
12. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.
Keene BW; Atkins CE; Bonagura JD; Fox PR; Häggström J; Fuentes VL; Oyama MA; Rush JE; Stepien R; Uechi M
J Vet Intern Med; 2019 May; 33(3):1127-1140. PubMed ID: 30974015
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
Smith PJ; French AT; Van Israël N; Smith SG; Swift ST; Lee AJ; Corcoran BM; Dukes-McEwan J
J Small Anim Pract; 2005 Mar; 46(3):121-30. PubMed ID: 15789807
[TBL] [Abstract][Full Text] [Related]
14. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of progression of chronic kidney disease in dogs with myxomatous mitral valve disease.
Yun H; Koo Y; Yun T; Chae Y; Lee D; Cha S; Kim J; Kim H; Yang MP; Kang BT
Front Vet Sci; 2023; 10():1200653. PubMed ID: 37691634
[TBL] [Abstract][Full Text] [Related]
16. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
Yata M; Kooistra HS; Beijerink NJ
J Vet Intern Med; 2019 Mar; 33(2):462-470. PubMed ID: 30703246
[TBL] [Abstract][Full Text] [Related]
17. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
Reimann MJ; Ljungvall I; Hillström A; Møller JE; Hagman R; Falk T; Höglund K; Häggström J; Olsen LH
Vet J; 2016 Mar; 209():113-8. PubMed ID: 26831162
[TBL] [Abstract][Full Text] [Related]
18. Two-dimensional echocardiographic estimates of left atrial function in healthy dogs and dogs with myxomatous mitral valve disease.
Dickson D; Caivano D; Matos JN; Summerfield N; Rishniw M
J Vet Cardiol; 2017 Dec; 19(6):469-479. PubMed ID: 29111284
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum myeloperoxidase concentration in dogs with heart failure due to chronic mitral valvular insufficiency.
Park JI; Suh SI; Hyun C
Can J Vet Res; 2017 Jan; 81(1):37-40. PubMed ID: 28154461
[TBL] [Abstract][Full Text] [Related]
20. Plasma atrial natriuretic peptide is an early diagnosis and disease severity marker of myxomatous mitral valve disease in dogs.
Ebisawa T; Ohta Y; Funayama M; Yamano S; Mizuno M; Mizuno T; Kasuya A; Sawada T; Lee J; Mizukoshi T; Uechi M
Res Vet Sci; 2013 Jun; 94(3):717-21. PubMed ID: 23312500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
